Leadership & Pay ·
Vivos Therapeutics, Inc. announced the voluntary resignation of Bradford Amman as Chief Financial Officer and…
VVOSVivos Therapeutics, Inc.
Vivos Therapeutics, Inc. announced the voluntary resignation of Bradford Amman as Chief Financial Officer and Secretary on July 31, 2026. Amman will serve as a non-executive transition employee for 90 days and an independent contractor advisor for an additional 180 days. His separation agreement includes continued salary during the transition, monthly advisory fees of $13,333, COBRA premium coverage, and equity grants of 250,000 shares and options to purchase 150,000 shares, with full vesting triggered by a completed equity financing of at least $5 million. The Board appointed Roman Franklin as the new Chief Financial Officer effective July 31, 2026. Franklin serves through The CFO Portal, LLC under a Master Services Agreement requiring an annual retainer of $324,000 and an equity award valued at approximately $237,360. Franklin will receive options to purchase 552,000 shares vesting monthly over twelve months. Vivos Therapeutics operates in the medical device industry, developing implantable neuromodulation devices for obstructive sleep apnea.